Consensus Prime Medicine, Inc.

Equities

PRME

US74168J1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
6.76 ^USD	+1.50%		+26.12%	-23.70%

May. 13	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating	MT
May. 10	Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Prime Medicine, Inc.

Price target over the last 5 years

History of analyst recommendation changes

695017525a57e8.rTrIy9La3TtyCr5rBVPxgo8P3cf6pb7dwvJCDBbCU_g.xVmujLCMvlIRWtgFNxLJ1to4mKOvw8S_jqF0fyXxEZvAcY68oe24dgRm9w~3f5644e6f9ac86adbf609edb6f8f3e01

Analyst Recommendations on Prime Medicine, Inc.

JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating	May. 13	MT
Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17	Apr. 22	MT
Chardan Initiates Prime Medicine at Buy With $17 Price Target	Apr. 22	MT
Wedbush Initiates Prime Medicine With Outperform Rating, $12 PT; Notes Positive Long-Term Outlook on Gene Editing Platform	Apr. 03	MT
Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating	Mar. 05	MT
Morgan Stanley Cuts Price Target on Prime Medicine to $12 From $18, Keeps Equalweight Rating	Dec. 12	MT
BMO Capital Starts Prime Medicine at Outperform, $19 Price Target	23-10-09	MT
Jones Trading Starts Prime Medicine at Buy With $20 Price Target	23-09-06	MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $19 From $21, Keeps Equalweight Rating	23-08-14	MT
Guggenheim Starts Prime Medicine at Buy With $24 Price Target	23-07-31	MT
Stifel Initiates Prime Medicine at Hold With $18 Price Target	23-04-18	MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $21 From $23, Maintains Equal-Weight Rating	23-01-24	MT
Goldman Sachs Starts Prime Medicine at Neutral With $22 Price Target	22-11-14	MT
JPMorgan Starts Prime Medicine at Overweight With $27 Price Target	22-11-14	MT
Jefferies Starts Prime Medicine at Buy With $25 Price Target	22-11-14	MT
Morgan Stanley Starts Prime Medicine at Equalweight With $23 Price Target	22-11-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.76 USD

Average target price

14.6 USD

Spread / Average Target

+115.98%

High Price Target

20 USD

Spread / Highest target

+195.86%

Low Price Target

9 USD

Spread / Lowest Target

+33.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Prime Medicine, Inc.

JPMorgan Chase
Chardan Research
Wedbush
Guggenheim
Morgan Stanley
BMO Capital
JonesTrading Institutional Services
Stifel Nicolaus
Jefferies & Co.
Goldman Sachs

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar